Close

Alto Pharma to introduce DermSafe hand sanitizer

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Alto Pharmaceuticals is set to introduce Skinvisible Pharmaceuticals’ DermSafe antimicrobial hand sanitizer in Canada on 1 September 2011.Under an agreement signed between both the companies, Skinvisible has given Canadian marketing rights of DermSafe to Alto. Alto expects to market the product under the name DermSafePC.DermSafe is made with 4% chlorhexidine gluconate and it does not contain delivers protection in a lotion formulation that defends the skin from outside irritants.Skinvisible president and CEO Terry Howlett said they believe that the introduction of DermSafePC will help generate a very positive response from end-users as well as potential licensees worldwide.

“The manufacturing of DermSafe in Canada is critical to Skinvisible as it will facilitate the quick introduction of the product in Europe and Singapore, where DermSafe is already approved for importation,” Howlett said.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back